JP2013509435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509435A5 JP2013509435A5 JP2012537131A JP2012537131A JP2013509435A5 JP 2013509435 A5 JP2013509435 A5 JP 2013509435A5 JP 2012537131 A JP2012537131 A JP 2012537131A JP 2012537131 A JP2012537131 A JP 2012537131A JP 2013509435 A5 JP2013509435 A5 JP 2013509435A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- injectable
- depot
- dose
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VOMKSBFLAZZBOW-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)CCCC4OC(=O)CCCCCCCCCCCCCCC)=NOC2=C1 VOMKSBFLAZZBOW-UHFFFAOYSA-N 0.000 claims description 18
- 229960000635 paliperidone palmitate Drugs 0.000 claims description 18
- 238000012423 maintenance Methods 0.000 claims description 16
- 210000003205 muscle Anatomy 0.000 claims description 8
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 230000000561 anti-psychotic effect Effects 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 239000000164 antipsychotic agent Substances 0.000 claims description 3
- 229940005529 antipsychotics Drugs 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000003405 delayed action preparation Substances 0.000 claims 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 229960001057 paliperidone Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 24
- 230000001839 systemic circulation Effects 0.000 description 3
- 210000000852 deltoid muscle Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25669609P | 2009-10-30 | 2009-10-30 | |
| US61/256,696 | 2009-10-30 | ||
| PCT/US2010/054807 WO2011053829A1 (en) | 2009-10-30 | 2010-10-29 | Dosing regimen associated with long-acting injectable paliperidone esters |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015237117A Division JP2016102123A (ja) | 2009-10-30 | 2015-12-04 | 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013509435A JP2013509435A (ja) | 2013-03-14 |
| JP2013509435A5 true JP2013509435A5 (enExample) | 2013-12-19 |
Family
ID=43302985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537131A Pending JP2013509435A (ja) | 2009-10-30 | 2010-10-29 | 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン |
| JP2015237117A Pending JP2016102123A (ja) | 2009-10-30 | 2015-12-04 | 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015237117A Pending JP2016102123A (ja) | 2009-10-30 | 2015-12-04 | 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20110105536A1 (enExample) |
| EP (1) | EP2493473A1 (enExample) |
| JP (2) | JP2013509435A (enExample) |
| KR (1) | KR20120116401A (enExample) |
| CN (1) | CN102802631A (enExample) |
| AU (2) | AU2010313290A1 (enExample) |
| BR (1) | BR112012010195A2 (enExample) |
| CA (1) | CA2742393A1 (enExample) |
| CL (1) | CL2012001110A1 (enExample) |
| MX (1) | MX2012005083A (enExample) |
| NZ (1) | NZ599558A (enExample) |
| WO (1) | WO2011053829A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| KR20100099292A (ko) | 2007-12-19 | 2010-09-10 | 얀센 파마슈티카 엔.브이. | 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법 |
| EP2547206B1 (en) | 2010-03-15 | 2016-05-11 | Inventia Healthcare Private Limited | Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
| MX358344B (es) | 2011-03-18 | 2018-08-15 | Alkermes Pharma Ireland Ltd | Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan. |
| CN102993200B (zh) * | 2011-09-10 | 2016-02-03 | 鲁翠涛 | 帕潘立酮氨基酸酯及其制备方法 |
| NZ630428A (en) * | 2012-03-19 | 2017-02-24 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising benzyl alcohol |
| EP2827868B8 (en) | 2012-03-19 | 2019-12-18 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| AU2013235523B9 (en) | 2012-03-19 | 2018-01-04 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| CN110368360A (zh) | 2014-03-20 | 2019-10-25 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
| SMT202000351T1 (it) * | 2015-04-07 | 2020-09-10 | Janssen Pharmaceuticals Inc | Regime di dosaggio per dosi mancate per esteri di paliperidone iniettabili ad azione prolungata |
| ITUB20155193A1 (it) * | 2015-11-03 | 2017-05-03 | Italfarmaco Spa | Sospensioni orali di Givinostat fisicamente e chimicamente stabili |
| WO2019173230A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| MX2022003646A (es) | 2019-09-25 | 2022-07-12 | Janssen Pharmaceuticals Inc | Interconexión de sistemas de administración de fármaco. |
| WO2022049006A1 (en) * | 2020-09-02 | 2022-03-10 | Janssen Pharmaceutica Nv | Pre-filled syringe with optimized stopper placement |
| EP4025189B1 (en) | 2020-11-30 | 2024-06-05 | Janssen Pharmaceutica NV | Dosing regimens associated with extended release paliperidone injectable formulations |
| PL4025187T3 (pl) | 2020-11-30 | 2024-04-29 | Janssen Pharmaceutica Nv | Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu |
| WO2022111859A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| WO2022195018A1 (en) * | 2021-03-17 | 2022-09-22 | Medincell S. A. | Long acting injectable formulation comprising risperidone and biodegradable polymers |
| US12472184B2 (en) | 2021-08-20 | 2025-11-18 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| KR100338776B1 (ko) | 2000-07-11 | 2002-05-31 | 윤종용 | 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법 |
| US20080214808A1 (en) | 2005-04-25 | 2008-09-04 | Thomas Frederik Ernestine Spittaels | Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester |
| US20070197591A1 (en) * | 2005-12-12 | 2007-08-23 | Sandra Boom | Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function |
| ES2304336T1 (es) * | 2006-08-14 | 2008-10-16 | Teva Pharmaceutical Industries Ltd. | Formas cristalinas de 9-hidroxi-risperidona (paliperidona). |
| KR20100099292A (ko) | 2007-12-19 | 2010-09-10 | 얀센 파마슈티카 엔.브이. | 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법 |
-
2010
- 2010-10-29 AU AU2010313290A patent/AU2010313290A1/en not_active Abandoned
- 2010-10-29 BR BR112012010195A patent/BR112012010195A2/pt not_active IP Right Cessation
- 2010-10-29 JP JP2012537131A patent/JP2013509435A/ja active Pending
- 2010-10-29 CN CN2010800504164A patent/CN102802631A/zh active Pending
- 2010-10-29 NZ NZ599558A patent/NZ599558A/en not_active IP Right Cessation
- 2010-10-29 CA CA2742393A patent/CA2742393A1/en not_active Abandoned
- 2010-10-29 WO PCT/US2010/054807 patent/WO2011053829A1/en not_active Ceased
- 2010-10-29 MX MX2012005083A patent/MX2012005083A/es not_active Application Discontinuation
- 2010-10-29 KR KR1020127013546A patent/KR20120116401A/ko not_active Ceased
- 2010-10-29 EP EP10773821A patent/EP2493473A1/en not_active Withdrawn
- 2010-11-01 US US12/916,910 patent/US20110105536A1/en not_active Abandoned
-
2012
- 2012-04-27 CL CL2012001110A patent/CL2012001110A1/es unknown
-
2013
- 2013-05-28 US US13/903,638 patent/US20130331402A1/en not_active Abandoned
-
2015
- 2015-10-16 AU AU2015243103A patent/AU2015243103A1/en not_active Abandoned
- 2015-12-04 JP JP2015237117A patent/JP2016102123A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013509435A5 (enExample) | ||
| NZ599558A (en) | Dosing regimen associated with long-acting injectable paliperidone esters | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| JP2014114288A5 (enExample) | ||
| JP2017031213A5 (enExample) | ||
| JP2015512392A5 (enExample) | ||
| JP2018510894A5 (enExample) | ||
| JP2011511072A5 (enExample) | ||
| JP2019196370A5 (enExample) | ||
| JP2016514132A5 (enExample) | ||
| IL273976B1 (en) | Methods and materials for nt-3 gene therapy | |
| JP2017538705A5 (enExample) | ||
| FI3998078T3 (fi) | Annoksensuurentamisentsyymikorvaushoito happaman sfingomyelinaasin puutoksen hoitamista varten | |
| JP2010531879A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| IL250302B (en) | Apoe mimetic peptides and higher potency to clear plasma cholesterol | |
| FI4119569T3 (fi) | Konjugoituja antisense-yhdisteitä käytettäviksi hoidossa | |
| JP2018531605A5 (enExample) | ||
| JP2019511506A5 (enExample) | ||
| RU2019107146A (ru) | Схемы и способы лечения рассеянного склероза с применением офатумумаба | |
| Gopalakrishna et al. | Long-acting injectable aripiprazole: how might it fit in our tool box? | |
| Remington et al. | 2012 CCNP Innovations Award Paper: Antipsychotic dosing: found in translation | |
| JP2016515137A5 (enExample) | ||
| RU2013150024A (ru) | Способы контроля и лечения хронической боли с применением hcg | |
| EP3141241A1 (en) | Sustained release low dose formulations and uses thereof |